Standard BioTools (NASDAQ:LAB) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Standard BioTools (NASDAQ:LAB) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Standard BioTools in a research report on Thursday, January 22nd. Zacks Research upgraded shares of Standard BioTools to a “hold” rating in a research note on Thursday, December 11th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Standard BioTools presently has a consensus rating of “Reduce” and a consensus price target of $1.35.

Standard BioTools Price Performance

Shares of NASDAQ LAB opened at $0.98 on Friday. The stock has a market capitalization of $384.06 million, a PE ratio of -4.92 and a beta of 1.36. Standard BioTools has a one year low of $0.92 and a one year high of $1.72. The business’s fifty day moving average price is $1.23 and its 200-day moving average price is $1.31.

Standard BioTools (NASDAQ:LAB) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.08. Standard BioTools had a negative return on equity of 11.21% and a negative net margin of 59.39%.The company had revenue of $23.80 million during the quarter, compared to analyst estimates of $18.50 million. As a group, equities analysts expect that Standard BioTools will post -0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Cibc World Markets Corp bought a new stake in shares of Standard BioTools during the fourth quarter valued at about $25,000. Aigen Investment Management LP bought a new position in shares of Standard BioTools in the fourth quarter valued at approximately $28,000. M&T Bank Corp bought a new position in shares of Standard BioTools in the fourth quarter valued at approximately $31,000. EntryPoint Capital LLC purchased a new position in Standard BioTools during the fourth quarter valued at approximately $31,000. Finally, Russell Investments Group Ltd. grew its stake in Standard BioTools by 2,989.0% during the third quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock valued at $33,000 after acquiring an additional 24,211 shares in the last quarter. Institutional investors own 53.74% of the company’s stock.

About Standard BioTools

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.